Alzheimer’s and amyloid: ‘It’s time to do something else’
If there is anything more certain than the failure of experimental Alzheimer’s drugs — nearly 300, at last count —
Read More
It Will Take More Than Transparency To Reduce Drug Prices, Economists Say
(By Alison Kodjak for NPR) A new drug to treat postpartum depression is likely to reach the U.S. market in
Read MoreFDA Chief Calls For Stricter Scrutiny Of Electronic Health Records
(Fred Schulte and Erika Fry, Fortune for Kaiser Health News) Food and Drug Administration Commissioner Scott Gottlieb on Wednesday called
Read MoreEven With Insurance, She Faced $227K In Medical Bills. What It Took To Get Answers.
(By JoNel Aleccia for Kaiser Health News) The first surprise was the massive heart attack, which struck as Debbie Moehnke
Read MoreHumana to expand primary care network
(By Morgan Haefner for Becker’s Hospital Review) Humana plans to extend its senior-focused primary care network to more cities, according
Read MoreBiogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment
(By Adam Feuerstein for STAT) Alzheimer’s disease has beaten back another effort to tame it. Biogen and its Japanese pharma
Read More“Affordability boards” to review expensive drugs
To rein in prescription drug prices, several states are considering new “affordability boards” to review expensive drugs and if it
Read MorePrescribing food as medicine is more cost effective
A new study suggests that prescriptions for healthy foods cold help lower the risk of expensive chronic illnesses like cardiovascular
Read MoreFentanyl-Linked Deaths: The U.S. Opioid Epidemic’s Third Wave
(By Martha Bebinger for NPR) Men are dying after opioid overdoses at nearly three times the rate of women in
Read MoreBiosimilar approval and adoption in the U.S. needs to be expedited
(By Carlos Sattler and Sheila Frame for STAT) Generic versions of brand-name small-molecule drugs saved Americans more than $1 trillion between 1999
Read More